Abstract–Infra-red spectra of twenty two metalphenanthroline perchlorates together with spectra of the free ligand, its hydrate and perchlorate salt have. Energy-Resolved Collision-Induced Dissociation Studies of 1,Phenanthroline Complexes of the Late First-Row Divalent Transition Metal Cations. A61K51/ Organic compounds complexes or complex-forming .. Embodiment The conjugate of any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8 and 9, For example, in case the first targeting moiety is targeting NTR1 the first targeting moetiy is Such chelators include, but are not limited to linear, macrocyclic.
|Published (Last):||9 August 2007|
|PDF File Size:||2.79 Mb|
|ePub File Size:||6.60 Mb|
|Price:||Free* [*Free Regsitration Required]|
Methods for determining the selectvitity factor of a compound such as the further targeting moiety to a or the target are known to the one skilled macrrocyclic the art and, for example described in Neubauer et al, J Med Chem,57, In an alternative embodiment the two reactive groups provided by the adapter moiety are the same.
Bioconjugate Chem2,wherein the group is preferably provided by an adapter moiety. The conjugate of the invention comprises general formula 1.
Phenanthroline – Wikipedia
The potentiometric titration reactions were measured with a personal computer PC system, as described previously [ 4 ]. It 100 within the present invention that a target to which the further targeting moiety of the conjugate of the invention is capable of binding, is a target that is expressed in an indication, preferably a tumor indication, whereby such target can be identified by methods known in the art. The conjugate of any one of embodiments 1 to 62, wherein the first target is same as the second target.
In an embodiment of the conjugate of the invention the target to which the further targeting moiety of the conjugate of the invention is capable of binding, is selected from the group comprising Alpha v beta 3 integrin, Alpha 5 beta lMoetyi v beta 6 integrin, Amino acid transporter ASC, Amino acid transporter L, Aminopeptidase N ANP, CD 13Angiopoietin-1 receptor, Atrial natriuretic peptide receptor 1, Atrial natriuretic peptide receptor 2, A-type amino acid transporter, Avidin, Bcr-Abl tyrosine phenanthrolinf, Bombesin receptor, Bombesin receptor macrocgclic, CA antigen, CA Indexed in Science Citation Index Expanded.
Silverman, Academic Press Ltd.
It is within the present invention that a target to which the further targeting moiety of the conjugate of the invention is capable of binding, is a target selected from the group of target classes comprising a GPCR, an ion channel, an adhesion molecule, an immunoglobulin superfamily receptor, a receptor tyrosine kinase, a receptor tyrosine phosphatase, a member of the tumor necrosis factor receptor family, an extracellular matrix protin, a transport, a matrix ckmplexes proteinase and CD molecules.
Neurotensin is bound by neurotensin receptors. Coordination chemistry is about tuning properties of metal ions using different ligands [ 1 — 3 ].
Bioinorganic Chemistry and Applications
As preferably used herein low density means that less than copies of NTR per cell are expressed. The conjugate of any one of embodiments 93 to 94, wherein the disease is selected from the group comprising tumors and hematological malignancies.
It also inhibited these pathogens by 5. The results on the stabilities and the structures of metal-Phen complexes analyzed in this study are presented in this article. The distribution diagram, computed by the SPE [ 29 ] software for a solution containing 9. View at Google Scholar E. Agonists and antagonists binding to NTR1 have been described in the prior art.
International Scholarly Research Notices
The conjugate of any one of embodiments 93 to 97, wherein Effector is a radioactive metal, wherein preferably the radioactive metal is chelated by Acceptor, wherein Acceptor is a chelator. The conjugate of embodiment 47, wherein the adapter moiety AD3 mediated the linkage between the second targeting moiety TM2 and the effector moiety EM.
Guanine is a chemically inert oxypurine heteroaromatic molecule. The conjugate of any one of embodiments 2 to 58, preferably embodiment 57, wherein the Effector is a diagnostically active nuclide, preferably a diagnostically active radionuclide, or a therapeutically active nuclide, preferably a therapeutically active radionuclide. TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target.
In accordance ,oetiy the present invention in the conjugate of the invention building block moiety [Z] b may be absent or be present in the form of a single building block Z or be present in the form of a polymer, wherein the polymer constists of a number of building blocks Z, wherein the number of building phenannthroline Z forming complsxes polymer is “b”, i. The conjugate of any one of embodiments 1 to 78, for use in a method for the diagnosis of a disease. Set,18, ; Cescato et al, J.
In this synthesis, Ru III and the ligands are brought together with rigid configuration. Molecular and Biomolecular Spectroscopyvol. Thyrotropin alfa TSH thyrotropin. One of said two neighbors is either the first adaptor moiety AD1 or, if the conjuage of the invention does not comprise a first adaptor moiety AD1, the first targeting moiety TM1.
Study of Metal-1,Phenanthroline Complex Equilibria by Potentiometric Measurements
The results given in Table 1 can be moetiiy as in the following equations 1 and 2. In an specific embodiment preactivated moieties can be assembled directly before use or even after or during in vivo application. TMl is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target.
Orexin AB Antagonists: This is an open access article distributed under the Creative Commons Attribution Licensewhich permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly phenanthrolne.